We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Weight Loss by State: Obesity Rates & Medicaid Coverage

Transformation Health Team October 17, 2026 6 min read

Adult obesity affects 33.1% of US adults as of 2024 (CDC Nutrition, Physical Activity, and Obesity - BRFSS), but the rate, and the help available to treat it, varies widely by state. The tables below show adult obesity prevalence for every state and DC, alongside whether each state’s Medicaid program covers GLP-1 medications for weight loss. Select your state for the full picture and what to compare when choosing a provider.

The 15 States With the Highest Adult Obesity Rates (2024) - chart by Transformation Health
Embed this chart on your site (free)

Copy this code. It credits Transformation Health with a link back to this page.

All 15 of these states exceed the 2024 national adult obesity rate of 33.1%.Source: CDC Nutrition, Physical Activity, and Obesity - BRFSS, 2024

A note on Medicaid: As of October 2026, our review of the 51 Medicaid programs (50 states and DC) found 8 that cover at least one GLP-1 medication for weight management, usually with prior authorization, 3 that cover them only under narrow conditions, and 8 that ended that coverage in 2025 or 2026. Coverage for type 2 diabetes is more common and is separate from weight-management coverage. Where covered, prior authorization is almost always required. Where a state does not cover these medications for weight loss, most people pay cash, through an in-person provider or a telehealth program whose providers are licensed in their state.

Adult obesity and GLP-1 Medicaid coverage by state

StateAdult obesityRankMedicaid (weight loss)
West Virginia41.4%1Generally not covered
Mississippi40.4%2Covered (with PA)
Louisiana39.2%3Generally not covered
Arkansas38.9%4Generally not covered
Alabama38.9%5Generally not covered
Indiana38.4%6Generally not covered
Nebraska37.6%7Generally not covered
Kansas37.6%8Covered (with PA)
Tennessee37.6%9Covered (with PA)
Wisconsin37.4%10Covered (with PA)
Kentucky37.2%11Generally not covered
South Dakota37.0%12Generally not covered
Ohio36.9%13Generally not covered
Oklahoma36.8%14Generally not covered
North Dakota36.8%15Generally not covered
Iowa36.6%16Generally not covered
Delaware36.6%17Covered (with PA)
Michigan36.1%18Restricted
Texas35.6%19Generally not covered
Georgia35.4%20Restricted
South Carolina34.6%21Recently ended
Missouri34.6%22Covered (with PA)
North Carolina34.5%23Covered (with PA)
New Mexico34.5%24Generally not covered
Pennsylvania34.2%25Recently ended
Nevada34.2%26Generally not covered
Illinois34.2%27Generally not covered
Alaska34.0%28Generally not covered
Oregon33.5%29Generally not covered
Arizona33.3%30Generally not covered
Maine33.2%31Generally not covered
Maryland32.7%32Generally not covered
Idaho32.7%33Generally not covered
Wyoming32.5%34Generally not covered
Virginia32.3%35Restricted
Minnesota32.3%36Covered (with PA)
Connecticut32.0%37Recently ended
Washington31.5%38Generally not covered
Rhode Island31.1%39Recently ended
New Hampshire31.1%40Recently ended
Utah31.0%41Recently ended
Montana31.0%42Generally not covered
Florida29.6%43Generally not covered
New York29.5%44Generally not covered
California29.1%45Recently ended
Vermont29.0%46Generally not covered
New Jersey27.7%47Generally not covered
Massachusetts27.0%48Recently ended
Hawaii27.0%49Generally not covered
District of Columbia25.5%50Generally not covered
Colorado25.0%51Generally not covered

Rank 1 = highest obesity prevalence. Full sources and methodology are listed below.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Data sources and methodology

  • Adult obesity: CDC Nutrition, Physical Activity, and Obesity, Behavioral Risk Factor Surveillance System. Prevalence is the percentage of adults with a body mass index of 30 or higher, based on self-reported height and weight, so figures may differ from measured surveys such as NHANES. National rate: 33.1% (2024).
  • Medicaid coverage: Transformation Health review of each state’s Medicaid preferred drug list, prior-authorization criteria, and provider notices, as of October 2026. Each state page links the state document used. Coverage changes frequently. Status shown here is for general information; confirm current benefits with your state Medicaid program.
  • Data current as of: 2024 CDC release. Page last updated: October 17, 2026.

Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. Medicaid coverage information is general and changes frequently; confirm with your state program. A licensed provider decides whether a prescription is appropriate. Results vary by individual. Transformation Health is an independent guide. It does not provide medical care, prescribe, or sell medication.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.